This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Menu
keyboard_arrow_right

CONFERENCE DAY 2

keyboard_arrow_leftSearch & Filter
search

CONFERENCE DAY 2

search
07:40 - 08:4060 mins
Registration
    Allogeneic CAR & T Cell Therapies – iPSc, NK, Gene Editing & Universal Cells
    08:40 - 08:455 mins
    Joint Plenary Session
    Chairperson’s Opening remarks
      08:45 - 09:0520 mins
      Joint Plenary Session
      Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
      • Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
      09:05 - 09:2520 mins
      Joint Plenary Session
      Non Gene edited Allogeneic cells
      • Philippe Parone - Industrialisation Lead, Celyad, USA
      09:25 - 09:4520 mins
      Joint Plenary Session
      Panel Discussion: Universal Cells: Is the Future for CGT Allogeneic ‘Off the Shelf’?
      • Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
      • Philippe Parone - Industrialisation Lead, Celyad, USA
      09:45 - 10:0520 mins
      Joint Plenary Session
      Spotlight Presentation
        10:05 - 10:2520 mins
        Joint Plenary Session
        Spotlight Presentation
          10:25 - 11:1550 mins
          Morning Coffee and Networking
            11:15 - 11:5035 mins
            STREAM 1: Cell Therapy
            Adherent Cell Manufacturing & Process Development
            • Manuel Carrondo - Professor of Chemical and Biochemical Engineering, FCT-UNL Vice-President, iBET Portugal
            11:15 - 11:5035 mins
            STREAM 2: Gene Edited Ex Vivo Cell Therapy
            Manufacturing Concepts for Gene-Edited Allogeneic CAR-T Cell Products
              11:15 - 11:5035 mins
              STREAM 3: In Vivo Gene Therapy
              Next Generation cell lines & large-scale bioprocessing technology
                11:15 - 11:5035 mins
                STREAM 4: Cell & Gene Therapy Connect: Partnering Track
                State of the Industry Report
                • Annie Hubert - Senior Director, European Policy, ARM (Alliance for Regenerative Medicine), Belgium
                11:50 - 12:2535 mins
                STREAM 1: Cell Therapy
                Risk Based Approaches to Comparability
                • Lior Raviv - Vice President, Pluristem Therapeutics Inc.
                11:50 - 12:2535 mins
                STREAM 2: Gene Edited Ex Vivo Cell Therapy
                Commercial Scale Manufacturing of Allogeneic Cell Therapy
                  11:50 - 12:2535 mins
                  STREAM 3: In Vivo Gene Therapy
                  Scale Up for Gene Therapy
                    11:50 - 12:2535 mins
                    STREAM 4: Cell & Gene Therapy Connect: Partnering Track
                    Panel Discussion : Strategies and Challenges in Manufacturing and Commercialization
                    • Kai Pinkernell - Chief Medical Officer (CMO) & Chief Development Officer, Medigene
                    12:25 - 12:5530 mins
                    STREAM 1: Cell Therapy
                    Spotlight presentation
                      12:25 - 12:5530 mins
                      STREAM 2: Gene Edited Ex Vivo Cell Therapy
                      Spotlight presentation
                        12:25 - 12:5530 mins
                        STREAM 3: In Vivo Gene Therapy
                        Spotlight presentation
                          12:25 - 12:5530 mins
                          STREAM 4: Cell & Gene Therapy Connect: Partnering Track
                          Spotlight presentation
                            12:55 - 14:1075 mins
                            Lunch, Networking and Live Labs
                              14:10 - 14:4535 mins
                              STREAM 1: Cell Therapy
                              Process Development Considerations for Exosomes
                                14:10 - 14:4535 mins
                                STREAM 2: Gene Edited Ex Vivo Cell Therapy
                                Advantages and challenges for manufacturing “Off-The-Shelf” Cell Therapy
                                  14:10 - 14:4535 mins
                                  STREAM 3: In Vivo Gene Therapy
                                  Characterization of Plasmid DNA Starting Materials
                                  • Lawrence Thompson, Ph.D., Pfizer
                                  14:10 - 15:2070 mins
                                  STREAM 4: Cell & Gene Therapy Connect: Partnering Track
                                  Partnering and Collaborations among Investors, Incubators and Biotechnology Companies
                                    14:45 - 15:2035 mins
                                    STREAM 1: Cell Therapy
                                    Starting Material Standardization
                                    • Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
                                    14:45 - 15:2035 mins
                                    STREAM 2: Gene Edited Ex Vivo Cell Therapy
                                    Starting Material Standardization
                                    • Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
                                    14:45 - 15:2035 mins
                                    STREAM 3: In Vivo Gene Therapy
                                    The Vector Production Gap: Harvesting & Purification Strategies
                                      15:20 - 15:5535 mins
                                      STREAM 1: Cell Therapy
                                      Spotlight presentation
                                        15:20 - 15:5535 mins
                                        STREAM 2: Gene Edited Ex Vivo Cell Therapy
                                        Spotlight presentation
                                          15:20 - 15:5535 mins
                                          STREAM 3: In Vivo Gene Therapy
                                          Spotlight presentation
                                            15:20 - 15:5535 mins
                                            STREAM 4: Cell & Gene Therapy Connect: Partnering Track
                                            Spotlight presentation
                                              15:55 - 16:2025 mins
                                              Afternoon Coffee
                                                16:20 - 16:5535 mins
                                                STREAM 1: Cell Therapy
                                                Selection & Management of Suppliers and Contract Service Providers
                                                  16:20 - 16:5535 mins
                                                  STREAM 2: Gene Edited Ex Vivo Cell Therapy
                                                  Raw Material Challenges for Gene Edited Allogeneic Products
                                                    16:20 - 16:5535 mins
                                                    STREAM 3: In Vivo Gene Therapy
                                                    Raw Material Challenges for Gene Edited Allogeneic Products
                                                      16:20 - 17:3070 mins
                                                      STREAM 4: Cell & Gene Therapy Connect: Partnering Track
                                                      Panel Discussion: Pricing and Reimbursement strategies for Cell and Gene Therapies
                                                      • Mike Fraser - General Manager of EMEA, AveXis Inc., Switzerland
                                                      16:55 - 17:3035 mins
                                                      STREAM 1: Cell Therapy
                                                      MSc as a Source Material
                                                        16:55 - 17:3035 mins
                                                        STREAM 2: Gene Edited Ex Vivo Cell Therapy
                                                        Efficiency Challenges as a Result Starting Materials in AAV Manufacturing
                                                          16:55 - 17:3035 mins
                                                          STREAM 3: In Vivo Gene Therapy
                                                          Efficiency Challenges as a Result Starting Materials in AAV Manufacturing
                                                            17:30 - 17:355 mins
                                                            Chairperson’s Closing Remarks
                                                              17:35 - 18:0530 mins
                                                              Spotlight Presentation
                                                                18:05 - 19:3590 mins
                                                                Networking Drinks and Evening Social Event
                                                                  CONFERENCE DAY 1
                                                                  NextCONFERENCE DAY 3
                                                                  Filter
                                                                  Streams
                                                                  Formats
                                                                  Choose Day